| Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. |
|
PloS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Pitfalls in Assessing Response to Treatment in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| New Approaches for Anemia in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| The Problem of TP53-Mutant MDS/AML |
|
Clinical Lymphoma , Myeloma & Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
|
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
|
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
| Guideline-based indicators for adult patients with myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium |
|
Pediatric Blood & Cancer |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Pediatric |
| A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the Nort |
|
Pediatric Blood & Cancer |
Aplastic Anemia, Pediatric |
